top of page

AVALUN - Ksmart® SARS COV-2 Antigen test achieves sensitivity of 91.3%

The Ksmart® SARS COV-2 Antigen test was validated in a randomized prospective clinical study performed in real life conditions in Clermont-Ferrand, France. The study was conducted by Gen-Bio laboratory in one of their COVID drive-through testing sites in November and December 2020. With a sensitivity of 91.3 % and a specificity of 99.0 % compared with a commercialized molecular assay, this study confirmed the high performances of the AVALUN’s unique solution for Covid Antigen testing which consists of the Ksmart® SARS COV2 Antigen test combined with the LabPad® Evolution automated reading device.

About the Ksmart® SARS COV-2 Antigen test

The Ksmart® SARS-COV2 Antigen Rapid Test is a qualitative membrane-based immunoassay for the detection of 2019-nCoV antigens assay for use with the LabPad® Evolution at the Point-of-Care. The automated LabPad® Evolution non operator dependent reading increases throughput with result available within 5 to maximum 20 minutes at the Point-of Care and allows for automatic reporting.

Click here for more information about the Ksmart® SARS-COV2 Antigen Rapid Test.


Os comentários foram desativados.
bottom of page